Oxadiazole Derivatives Research Articles

Systematic Review on 1,2,3-Oxadiazoles, 1,2,4-Oxadiazoles, and 1,2,5-Oxadiazoles in the Antimycobacterial Drug Discovery.

Tuberculosis remains a leading global health threat, exacerbated by the emergence of multi-drug-resistant strains. The search for novel therapeutic agents is critical in addressing this challenge. This review systematically summarizes the potential of oxadiazole derivatives as promising candidates in antimycobacterial drug discovery. We focus on various classes of oxadiazoles, especially 1,2,3-oxadiazoles, 1,2,4-oxadiazoles, and 1,2,5-oxadiazoles, highlighting their structural diversity and biological activities. Recent advancements in structure-activity relationship studies are discussed, emphasizing the mechanisms of antimycobacterial action. Additionally, the synergistic potential of 1,2,4-oxadiazoles in enhancing the efficacy of existing tuberculosis treatment with ethionamide is also discussed. By integrating insights from recent research, this review aims to provide a comprehensive overview of the role of oxadiazoles in the fight against tuberculosis, paving the way for future investigations and the development of effective therapeutic strategies.

Insight into the Novel Synthesis Approaches and Biological Activity of 1,3,4 Oxadiazole: A Review

Oxadiazole is an organic compound featuring a heterocyclic ring housing carbon, oxygen, and nitrogen atoms. Due to their heightened stability in biological environments, oxadiazole rings exhibit significant biological activities, effectively addressing health challenges like infectious diseases and chronic conditions in medicinal chemistry. The main objective of this review is to discuss various synthetic approaches related to 1,3,4-oxadiazole and its derivatives. The diverse reactivity positions oxadiazole as a valuable building block in organic synthesis, with derivatives exhibiting promising pharmacological activities. It involves a systematic literature review, critical analysis, and synthesis of existing research. This review comprises the ever-expanding chemical knowledge and has significant implications for drug development. Synthetic approaches to synthesizing oxadiazole through different schemes and methods have been discussed thoroughly. This review also concisely associated the pharmacological activities of oxadiazole and its derivatives. This review highlights the importance of continued research into the structure-activity relationships of oxadiazole derivatives, paving the way for developing novel and more potent therapeutic agents.

In Vivo Screening and In Silico Structure-Based Characterization of Synthesized Oxadiazole Derivatives with Potential Anticonvulsant Activity

In Vivo Screening and In Silico Structure-Based Characterization of Synthesized Oxadiazole Derivatives with Potential Anticonvulsant Activity

Design, Synthesis, and Biological Evaluation of New Oxadiazole Derivatives as Efficient Antihypertension Drugs.

A series of novel oxadiazole derivatives were designed, synthesized, and evaluated for their pharmacological effects. All target compounds were subjected to analysis using 1H NMR, 13C NMR, and mass spectrometry. They showed a strong affinity to the AT1 receptor and effectively lowered blood pressure in spontaneously hypertensive rats at a nanomolar level. Compounds IV1 and IV2 were particularly effective, demonstrating comparable or greater potency in reducing blood pressure compared to Losartan. Therefore, compounds IV1 and IV2 have the potential to be developed as antihypertension medications.

Synthesis and Biological Evaluation of some 2,5-Disubstituted -1,3,4- Oxadiazole Derivatives

Synthesis of some new 2, 5-diaryl-1, 3, 4-oxadiazole derivatives starting from Isoniazide (INH) is described. The target compounds 11- 20 were obtained by treating INH with various aromatic aldehydes and monosaccharides to give corresponding Schiff ’s bases 1- 10, which upon subsequent oxidation, by using either method A, B or C, yielded desired compounds. They were purified and characterized by spectroscopic techniques and elemental analyses. These compounds were evaluated for antibacterial, antifungal and antiviral activities. Compounds 11, 16 and 17 exhibited good antibacterial and antifungal activity, however, none of the compounds were enough active against various strains of virus.

Synthesis and Antifungal Activity of 5-Trifluoromethyl-1,2,4-oxadiazole derivatives Containing Hydrazide Group as Potential Fungicides

To further investigate the potential fungicide with heterocyclic moiety, three new 5-trifluoromethyl-1,2,4- oxadiazole derivatives derivatives containing hydrazide group were designed, synthesized, and assayed for inhibitory activity against plant pathogenic fungi. Especially, compound 3a presented excellent in vitro antifungal activity against Valsa mali and Botryosphaeria dothidea, which was substantially stronger than chlorothalonil. In vivo antifungal assay revealed that compounds 3a and 3b exhibited prominent protective activity against soybean rust, which were at the same level with benzovindiflupyr. These results indicated that 5-trifluoromethyl-1,2,4-oxadiazole derivatives could be a potential fungicide lead.. KEYWORDS :5-trifluoromethyl-1,2,4-oxadiazole derivatives, Antifungal activity, Hydrazide.

Molecular Dynamics of a N-Cyclohexyl-1,2,4-Oxadiazole Derivative as a Reversible Cruzain Inhibitor in Trypanosoma cruzi.

Chagas disease kills around 10,000 people yearly, primarily in Latin America, where it is prevalent. Current treatment has limited chronic effectiveness, is unsafe, and has substantial side effects. As a result, the use of oxadiazole derivatives and similar heterocyclic compounds as bioisosteres are well known, and they are prospective candidates in the hunt for novel anti-Trypanosoma cruzi chemicals. Recent research has revealed that the cysteine protease cruzain from T. cruzi is a validated target for disease treatment. Thus, using a molecular dynamics simulation, the current study attempted to determine if a significant interaction occurred between the enzyme cruzain and its ligand. Interactions with the catalytic site and other critical locations were observed. Also, the RMSD values suggested that the molecule under research had stable interactions with its target. Finally, the findings indicate that the investigated molecule 2b can interfere enzymatic activity of cruzain, indicating that it might be a promising antichagasic drug.

Synthesis, quantum chemical insights, vibrational spectral elucidation, insecticide likeness and docking analysis of the insecticide active novel molecule 2-(4-nitrophenyl)-(3,5-difluoro-pyridine-6-yl)-1,3,4-oxadiazole

Oxadiazole derivatives containing pyridine moiety were biologically active molecules that have been widely applied in recent years in research on pesticides, particularly insecticides. In this work, a newly synthesized 2-(4-nitrophenyl)-(3,5-difluoro-pyridine-6-yl)-1,3,4-oxadiazole compound was characterized using spectroscopic techniques. The quantum chemical computations based on density functional theory were employed to investigate the molecular configuration of title compound. The modes of vibrations of the compound were identified through potential energy distribution, and the results were consistent with the experimental infrared and Raman data. Natural bond orbital assessment evaluated the significant donor-acceptor interactions within the molecule. The frontier molecular orbital analysis was performed to obtain global reactivity parameters. The molecular electrostatic potential was used to visualize the chemical reactivity and charge distribution of the molecule. From the nuclear magnetic resonance spectra, the carbon atoms bonded with nitrogen and oxygen atoms show the up-shielded peaks. The chemical implication of molecule was explained using electron localization function and localized orbital locator analysis. Moreover, the molecular docking studies performed for the newly synthesized compound revealed an efficient interaction with the acetylcholine receptor and exhibited better binding affinity than commercialized insecticides. Whilst, the physicochemical properties were assessed using the insectiPAD webtool to comprehend the insecticidal properties of title compound. Finally, the quantitative structure activity relationship study of 2-(4-nitrophenyl)-(3,5-difluoro-pyridine-6-yl)-1,3,4-oxadiazole showed higher activity (pLC50 = −1.43) against Mythimna separata, as compared to commercial insecticide avermectin (pLC50 = −1.47). These results provided that title compound could be used as a template for future insecticide investigations.

Molecular Docking and Modelling Studies for Identifying Novel Oxadiazole Derivatives to Inhibit COX-2 Enzyme as an Anti-Inflammatory Treatment

The objective of the study was to develop new Oxadiazole compounds using docking simulation studies for inhibitory action against the Cycloxoygenase-2(COX-2) enzyme. The study aimed at the development and identification of novel and potent derivatives of 1,3,4-oxadiazole for targeting anti-inflammatory disease by screening their inhibitory action against COX-2 enzyme with schrodinger molecular docking software and molecular simulation by GROMACS 2022. A library of 375 novel compounds of 1,3,4-oxadiazoles derivatives was designed and proposed for docking against cyclooxygenase-2 enzyme (COX-2)PDB ID: 6BL4, which was downloaded from protein data bank site https://www.rcsb.org/. MD simulations for three models were performed, namely, compound A-Cox-2, E-Cox-2, and G-Cox-2, for 100 ns. Out of 375 proposed compounds, the top 16 compounds with good docking scores and binding energy were selected for further ADME profile studies in which all compounds showed good results as compared to Standard drugs. RMSD values of 0.2 nm showed that all ligand-Cox-2 complexes were stable during simulation. Compound G was the most efficient in decent interactions with the residues ARG120 and TYR355 of cyclooxygenase- 2, which were stable for 29.32, 21.52, and 12.00% duration of simulation along with comparatively better h-bond contacts. All potential inhibitors met Lipinski's rule of five, indicating oral availability. The potential compounds may be further evaluated for pharmacological activities using different in vitro and in vivo evaluations.

Anticancer activity of EMD37 against human head and neck cancer: Impact on apoptotic and inflammatory machineries

Accumulating evidence emphasizes the tumorigenic role of epidermal growth factor receptor (EGFR) in head and neck cancer (HNC). Although cetuximab is the sole anti-EGFR approved by the Food and Drug Administration for treating HNC patients.its response rates are modest. Thus, novel effective and tolerable therapeutic strategies are urged. We previously reported the capability of oxadiazole derivatives to degrade tyrosine kinase receptors including EGFR and exhibit potent anticancer activities against NCI-60 panel which does not include HNC. The aim of this study was to investigate the potential anticancer activity of EMD37, a novel 1,2,4-oxadiazole derivative, against human HNC cells and if effective, to examine the effect of EMD37 on apoptotic and inflammation mediators. Indeed, EMD37 exhibited potent cytotoxicity against patient-derived HNC cell lines (HNO-97, HN-9 and FaDu). Delving deeper, EMD37 triggered intrinsic and extrinsic apoptosis in HNC cells as evidenced by increased levels of caspase-8, caspase-9, caspase-3, caspase-7, caspase-6, TP53BP1 tumor suppressor and Bax, and downregulated anti-apoptotic Bcl-2 protein. EMD37 also significantly abrogated the levels of pro-inflammatory interleukin-1β, interleukin-6, cyclooxygenase-2 and matrix metalloproteinases (MMP-2 and MMP-9) which are heightened in HNC. Bioinformatic analysis revealed that BCL2low, IL6low and MMP9low HNC biospecimens are enriched with epithelial cell differentiation gene set, and CASP8high cohort is enriched with extrinsic apoptosis. Altogether, this study emphasizes the therapeutic potential of targeting the apoptotic and inflammatory machineries in HNC using EMD37.

Parkinson's Disease: Unravelling the Medicinal Perspectives and Recent Developments of Heterocyclic Monoamine Oxidase-B Inhibitors.

Parkinson's disease is a neurodegenerative condition characterized by slow movement (bradykinesia), tremors, and muscle stiffness. These symptoms occur due to the degeneration of dopamine- producing neurons in the substantia nigra region of the brain, leading to reduced dopamine levels. The development of Parkinson's Disease (PD) involves a combination of genetic and environmental factors. PD is associated with abnormal regulation of the monoamine oxidase (MAO) enzyme. Monoamine oxidase inhibitors (MAOIs) are an important class of drugs used to treat PD and other neurological disorders. In the early stages of PD, monotherapy with MAO-B inhibitors has been shown to be both safe and effective. These inhibitors are also commonly used as adjuncts in long-term disease management, as they can improve both motor and non-motor symptoms, reduce "OFF" periods, and potentially slow disease progression. However, current MAO-B inhibitors come with side effects like dizziness, nausea, vomiting, light-headedness, and fainting. Therefore, accelerating the development of new MAO-B inhibitors with fewer side effects is crucial. This review explores natural compounds that may inhibit monoamine oxidase B (MAO-B), focusing on key findings from the past seven years. It highlights the most effective heterocyclic compounds against MAO-B, including thiazolyl hydrazone, pyridoxine-resveratrol, pyridazine, isoxazole, oxadiazole, benzothiazole, benzoxazole, coumarin, caffeine, pyrazoline, piperazine, piperidine, pyrrolidine, and morpholine derivatives. The review covers in vitro, in silico, and in vivo data, along with the structure- activity relationship of these compounds. These findings offer valuable insights for the development of more effective MAO-B inhibitors and advancements in Parkinson's disease research.

1,3,4-Oxadiazole Scaffold in Antidiabetic Drug Discovery: An Overview.

Diabetes mellitus is one of the biggest challenges for the scientific community in the 21st century. With the increasing number of cases of diabetes and drug-resistant diabetes, there is an urgent need to develop new potent molecules capable of combating this cruel disease. Medicinal chemistry concerns the discovery, development, identification, and interpretation of the mode of action of biologically active compounds at the molecular level. Oxadiazole-based derivatives have come up as a potential option for antidiabetic drug research. Oxadiazole is a five-membered heterocyclic organic compound containing two nitrogen atoms and one oxygen atom in its ring. Oxadiazole hybrids have shown the ability to improve glucose tolerance, enhance insulin sensitivity, and reduce fasting blood glucose levels. The mechanisms underlying the antidiabetic effects of oxadiazole involve the modulation of molecular targets such as peroxisome proliferator-activated receptor gamma (PPARγ), α-glucosidase, α-amylase and GSK-3β which regulate glucose metabolism and insulin secretion. The present review article describes the chemical structure and properties of oxadiazoles and highlights the antidiabetic activity through action on different targets. The SAR for the oxadiazole hybrids has been discussed in this article, which will pave the way for the design and development of new 1,3,4-oxadiazole derivatives as promising antidiabetic agents in the future. We expect that this article will provide comprehensive knowledge and current innovation on oxadiazole derivatives with antidiabetic potential and will fulfil the needs of the scientific community in designing and developing efficacious antidiabetic agents.

Synthesis of pyridin-3-yl-1,3,4-oxadiazole and 5-p-tolyl-1,3,4-oxadiazole derivatives and their evaluation as antihyperglycemic agents, AChE and BuChE inhibitors, and antioxidants

Thirty oxadiazole derivatives 1–30 were synthesized via nucleophilic substitution reactions between 1,3,4-oxadiazole-2-thiol and benzyl/phenacyl halides. The structural elucidation of compounds was done by EI-MS, HREI-MS, 1HNMR , and 13CNMR . The compounds were divided into three categories based on their substitution patterns. Among thirty synthetic compounds, four compounds, 13, 14, 15, and 19, were found to be new. The inhibitory activities of compounds were evaluated against α-amylase, α-glucosidase, AChE, and BuChE in vitro. Compound 8 (IC50 = 20.71 ± 0.16; 19.04 ± 0.52 µM), possessing a 2-chloro-4-fluoro benzyl ring, demonstrated the highest antihyperglycemic activity among these oxadiazoles. Despite showing slightly lower activity than the standard acarbose (IC50 = 13.19 ± 0.26; 16.28 ± 0.24 µM), it can be a potential candidate for further exploration as an antihyperglycemic agent. Compound 16 (IC50 = 7.33 ± 0.02; 9.5 ± 0.16 µM) containing an unsubstituted phenacyl group demonstrated the highest inhibitory potential against AChE and BChE enzymes as compared to the standard donepezil with IC50 values of 2.05 ± 0.12 µM and 4.02 ± 0.06 µM. Molecular docking analysis revealed favorable interactions, including hydrogen bonding, hydrophobic, and π-π stacking interactions between the compounds and the target proteins. Additionally, the antioxidant potential of the compounds was assessed using DPPH and ABTS radical scavenging assays, and compounds revealed significant activities. The study provides valuable insights into the structure-activity relationship of these compounds, which could guide future drug design efforts for more potent enzyme inhibitors.

A new N-acylhydrazone oxadiazole derivative with activity against mycobacteria.

Aim: To evaluate the anti-Mycobacterium tuberculosis (Mtb) potential of the hybrid oxadiazol-4-methoxynaphthalene (6n) derived from N-acylhydrazone (4k).Materials & methods: The study determined the minimal inhibitory concentration of (6n) against Mtb H37Rv and Mtb clinical isolates, potential combination of (6n) with anti-tuberculosis drugs and carried out time kill curve assay of Mtb H37Rv. Additional contribution for the analysis of (6n) was explored by in silico pharmacokinetics, and in vitro and in vivo cytotoxicity determinations.Results: The newly synthesized molecule (6n) demonstrated anti-Mtb activity, low cytotoxicity and selectivity for Mtb.Conclusion: The derivative (6n) emerges as a potential anti-TB drug candidate.

Novel Ag(I)‐based 1,2,4‐Oxadiazole Complexes: Synthesis, X‐Ray Crystal Structure, and Biological Evaluation as Anticancer Candidates

ABSTRACTThe 3,5‐diaryl‐1,2,4‐oxadiazole scaffolds 2 and 3 were synthesized and used as ligands to obtain three novel Ag(I) complexes 4–6. The structure of the Ag(I) complexes 4–6 has been confirmed by single crystal X‐ray diffraction. Complex 4 has the dinuclear formula [Ag(2)(NO3)]2. 5 and 6 are monomeric complexes having the formula [Ag(3)2(NO3)] and [Ag(3)2]ClO4, respectively. In vitro, trypsin, ALDH2, and iNOS inhibition activities were assessed for the free ligands and their Ag(I) complexes. Interestingly, Ag(I) complexes 4–6 revealed more prominent trypsin inhibitory activity than the ligands 2 and 3. The oxadiazole derivative 3 and its Ag(I) complex (6) showed significant ALDH2 inhibition (45% and 55%, respectively). Complex 6 (IC50 = 35.61 μM) surpassed its 1,2,4‐oxadiazole ligand 3 (IC50 = 88 μM) and evidenced the most prominent ALDH2 inhibitory activity. The oxadiazole derivative 3 and its corresponding Ag(I) complexes 5 and 6 showed significant iNOS inhibition (77.77%, 84.12%, and 84.15%, respectively). With IC50 values of 18.13, 18.15, and 13.96 μM, respectively, complex 6 is the most potent against iNOS, surpassing the reference standard.

Cover Feature: Tetrazole and Oxadiazole Derivatives as Thermally Activated Delayed Fluorescence Emitters (Chem. Eur. J. 57/2024)

Cover Feature: Tetrazole and Oxadiazole Derivatives as Thermally Activated Delayed Fluorescence Emitters (Chem. Eur. J. 57/2024)

A versatile inhibitory approach and molecular mechanism on cancer cells and cholinesterase enzymes: Synthesis, DFT, ADMET and molecular docking of thiadiazole and oxadiazole derivatives

This study presents a multi-routed research design featuring thiadiazole/ oxadiazole based Schiff base derivatives as potential inhibitors, targeting cancer and Alzheimer. Among thiadiazole based Schiff base derivatives, the excellent inhibition was exhibited by compound 1 (IC50 = 20.10 ± 1.1, 22.21 ± 1.03 and 26.23 ± 2.2 µM for HepG2 (liver cancer), MCF-7 (breast cancer) and W138 (lung cancer), respectively) in comparison to the standard Doxorubicin. Oxadiazole based compound 9 was also found with spellbinding efficacy (IC50 =15.20 ± 2.5, 19.13 ± 2.2 and 12.33 ± 3.4 µM for HepG2, MCF-7 and W138, respectively). Both compounds 1(IC50=3.10 ± 0.20 and 3.70 ± 0.10 µM against AChE and BuChE) and 9 (IC50=2.20 ± 0.10 and 2.80 ± 0.50 µM against AChE and BuChE) were also found as excellent anti-Alzheimer agents in comparison to reference donepezil. The outcomes of in vitro biological activity were further studied in silico via molecular docking, DFT and ADMET to elucidate the binding interactions, stability, reactivity and pharmacokinetic profiles of potent compounds.

Synthesis of New Heterocyclic Derivatives from 4-(3, 5-Dimethyl-1-phenyl-1H-pyrazol-4-ylazo)- benzoic acid

In this work pyrazolin derivatives were prepared from the diazonium chloride salt of 4-aminobenzoic acid. Azo compounds were prepared from the reaction of an ethanolic solution of sodium acetate and calculated amount of active methylene compound namely, acetyl acetone to obtain the corresponding hydrazono derivative (1). Cyclocondensation reaction of compounds (1) with hydrazine hydrate and phenyl hydrazine in boiling ethanol affording the corresponding pyrazoline-5-one derivatives of 4-aminobenzoic acid (2,3). Then compound (3) was reacted with thionyl chloride to give the corresponding acid chloride derivative(4), followed by conversion into the corresponding acid hydrazide derivative (5) carboxylic acid thiosemicarbazide (11), esters (14,15), thioesters (16,17) and amides (18,19), when treated hydrazine hydrate, thiosemicarbazide, alcohols, alkylthiol and secondary amines in dry refluxing benzene; respectively. Schiff's bases (6-8) were prepared by refluxing of compound (5) with different aldehydes and ketons, then two compounds from the Schiff's bases were cyclized with ?-mercapto acetic acid to give (9 and 10). Furthermore, 1,2,4-triazole derivative (12) have been also prepared by refluxing thiosemicarbazide derivative with sodium hydroxide solution (4%) followed acidification of the result using (10%)hydrolic acid. Moreover, a thiadiazole derivative (13) has been prepared by treatment of thiosemicarbazide derivative with concentrated sulfuric acid as cyclyzing agent. Finally, oxadiazole derivative (20) has prepared by condensation of its acid hydrazide derivative with carbon disulfide in basic medium.

Novel benzothiophene‒tethered 1,3,4‒oxadiazoles as potent antimicrobial targets: Design, synthesis, biological evaluation, DFT exploration and in silico docking study

Based on previous developments of oxadiazole research programs in trying to find novel compounds with multiple biological targets, such as antibacterial and antitubercular medications. In the context, a new series of 1,3,4-oxadiazole derivatives based on benzo[b]thiophene moiety 6a‒d, 7a‒d, and 8a‒d was synthesized from 5-(3-methylbenzo[b]thiophen-2-yl)-1,3,4-oxadiazole-2-thiol. The structures of 1,3,4‒oxadiazole derivatives were elucidated via NMR (1H and 13C), IR, and HRMS spectrum data as well as physical data. Subsequently, the derivatives were evaluated for their inhibitory activity against different bacterial microorganisms, and the MICs were determined in vitro tubercular activity against the sensitive M. tuberculosis H37Rv strain. Remarkably, hybrids 6c and 7a exhibited excellent antibacterial activity against S. aureus with ZI values of 31 ± 0.99, and 30 ± 0.32 mm, and it has been noticed that 8b demonstrated the most prominent antibacterial efficiency with MICs = 3.1, 3.6, 5.6, and 5.1 μg/mL against S. pneumoniae, S. pyrogenes, E. coli, and K. pneumoniae. Among them, compound 8b, featuring a benzo[b]thiophene moiety linked to oxadiazole, exhibited a significant tubercular inhibitory effect with an MIC value of 2.2.5 μM. Additionally, the docked compound 7a showed the strongest key active key amino acids Arg44(A), Arg45(A), Ala126(A), Gly18(A), Ser49(A), Asp48(A) in the antitubercular active site of 1DG5 protein. The study of computer aided ADMET was also carried out, using SwissADME and ADMETlab2.0 to investigate the pharmacokinetic properties of the tested triazole compounds. To support the experimental data, molecular docking and density functional theory (DFT) studies help in understanding the interactions better.

Overcoming methicillin resistance by methicillin-resistant Staphylococcus aureus: Computational evaluation of napthyridine and oxadiazoles compounds for potential dual inhibition of PBP-2a and FemA proteins

Abstract The treatment of the various infections caused by Staphylococcus aureus has become challenging due to the evolving resistance against current therapeutics. In this study, the potentials of napthyridine and oxadiazole derivatives to serve as dual inhibitors of penicillin-binding protein 2a (PBP-2a) and FemA protein, which are crucial to resistance to methicillin-based drugs by S. aureus, were evaluated using molecular modeling techniques. Seventy-two compounds were subjected to molecular docking against the proteins, and the hit compounds were subjected to drug-likeness evaluation and in silico pharmacokinetics prediction. The compounds with good safety profiles were subjected to a 250-ns molecular dynamics (MD) simulation and other relevant analyses based on the MD trajectories. Five hit compounds were selected based on their high affinity for the targets as evidenced by their docking scores ranging from −8.6 to −10.1 kcal/mol for PBP-2a and −9.6 to −9.9 kcal/mol for FemA. These compounds also passed Lipinski’s rule of five evaluation with no violation and possessed high human intestinal absorption potential, showcasing their potential as orally administered therapeutic agents. However, three of the compounds were potential mutagens. MD simulation revealed that the final two compounds maintained stable interactions with the target proteins over 250 ns, with minimal deviations and fluctuations. Hydrogen bond stability and energy decomposition analysis further confirmed the strong binding affinity of the hit compounds compared to the control drug, methicillin. Conclusively, the compounds with the CID “135964525” and “44130718” are worthy of further experimental validation in the development of potential inhibitors of PBP-2a and FemA.